Article
Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin's clinical durability.
PLoS pathogens - 1 Aug 2024
Blechman Samuel E, Wright Erik S
Abstract excerpt
Vancomycin has proven remarkably durable to resistance evolution by Staphylococcus aureus despite widespread treatment with vancomycin in the clinic. Only 16 cases of vancomycin-resistant S. aureus (VRSA) have been documented in the United States. It is thought that the failure of VRSA to spread is partly due to the fitness cost imposed by the vanA operon, which is the only known means of high-level resistance....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
